Search
Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study
Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.
Read moreEHA-SWG Scientific Meeting on Immunotherapy for Hematological Disorders
EHA and the Scientific Working Group on Immunotherapy for Hematological Disorders are happy to announce the redesigned fully virtual meeting program to meet the needs of hematologists and immunologists in these challenging times.
Read moreGood Governance Committee
Current committee members
Wim Fibbe, Netherlands (Chair)
Laurent Degos, France
Jean-Luc Harousseau, France
Cristina Mecucci, Italy
Helen Papadaki, Greece
Irene Roberts, United Kingdom
Pieter Sonneveld, Netherlands
AimThe Good Governance Committee (GGC) is responsible for guarding EHA’s image, position and performance as a non-profit membership organization for the public…
Highlights of Past EHA (HOPE) Latin America (LA) 2019
Dates: October 4-5, 2019
Location: Mendoza, Argentina
Chairs:
Prof Dorotea Fantl, President, Sociedad Argentina de Hematología (SAH)
Prof Marivi Mateos, EHA Executive Board Member, European Hematology Association (EHA)
EHA, in partnership with the Sociedad Argentina de Hematología (SAH), is bringing the key messages from the…
Leading Medical Organizations Join Forces Globally to Launch First-Ever World Thrombosis Day
“We must reduce the burden from thrombosis if we are to achieve the World Health Assembly’s global target of reducing mortality from premature non-communicable disease by 25 percent by 2025,” said Gary Raskob, Ph. D.
Read more